Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors
Varricchi G, Galdiero MR, Mercurio V, Bonaduce D, Marone G, Tocchetti CG
Lancet Oncol. 2018 Dec;19(12):1545-1546
CARDIONCOLOGY.ORG ABSTRACT:
Immune checkpoint inhibitors (ICIs) are now a cornerstone in cancer treatments.
Though ICIs, such as monoclonal antibodies directed against CTLA-4, PD-1, and PD-L1 have revolutionized anticancer strategies, these drugs are also associated with some risk of cardiotoxicity.
© All rights reserved
Image source: https://www.wjgnet.com/2219-2824/full/v5/i1/WJI-5-1-g001.htm